The 2020 CIPA Life Sciences Webinar Series
Thursday 19th November 2020
Topic: Sufficiency in the English Courts - The Regeneron Story and Practical Implications
Date: Thursday 19th November, 2020
Time: 12:00 - 1:15pm GMT
Agenda to Include:
Discussion of the decision and impact on filing strategies
Shohta Ueno, Regeneron
Current role: Director, Dispute Resolution at Regeneron Pharmaceuticals Inc a leading biopharmaceutical company based in Tarrytown New York where I help the company navigate through complex dispute resolutions. While I deal with all matters related to dispute resolution a large proportion of my time is dedicated to navigating through complex IP landscape. I am the only disputes lawyer for the company based outside of the US, and am therefore involved in all disputes outside of the US. I joined Regeneron in October 2018.
Before joining Regeneron, I worked at Allen & Overy in London as part of the IP litigation team and advised on matters with a high scientific and technological content often working with world leading experts. Key highlight include advising Regeneron on asserting its patents relating to a novel platform for producing antibody therapies using transgenic mice. In this case, I had the opportunity to work with eminent scientists including a world leading immunologist from MIT and a Nobel prize winning molecular biologist. I have a technical background with PhD in Virology.
Katie Coltart, Kirkland & Ellis
Katie Coltart is a partner in Kirkland & Ellis’ London IP Litigation team. Katie focuses her practice on patent litigation, particularly in the life sciences and tech sectors. Katie is experienced in dealing with multi-jurisdictional cases requiring significant cross-border coordination across multiple forums at both first instance and on appeal. Katie has litigated patents across a broad spectrum of technological subject matters including those relating to antibody and other protein biologics, biological product development and screening platforms, checkpoint inhibitor immunotherapies, diagnostics and next generation sequencing technologies, medical devices, wireless and mobile telecommunications, and consumer product technologies.
With a degree in Natural Sciences (Chemistry and Biology) Katie is well placed to advise her life sciences clients on their most technical subject matter. Katie has been ranked for the past two years as a ‘Next Generation Partner’ for Intellectual Property by The Legal 500. She is also ranked as an ‘IP Trailblazer’ in World Intellectual Property Review’s Influential Women in IP 2019; and a WIPR Leader by World Intellectual Property Review.
James Nicholls, J A Kemp
Jimmy Nicholls is a European Patent Attorney and UK Chartered Patent Attorney, with a PhD in Molecular Biology. He joined J A Kemp as a trainee in 2006 and became a partner in their Biotechnology and Life Sciences team in 2016. He is based in J A Kemp’s Paris Office, having previously also worked in their London and Oxford offices. Jimmy has been involved since early in his career in prosecuting and defending Regeneron’s patent portfolio relating to their transgenic mouse antibody discovery platform before the EPO, and provided support for the parallel UK litigation.
Nicole Jadeja, Pinsent Masons
Nicole Jadeja is a life sciences partner at Pinsent Masons who enjoys resolving IP disputes and providing strategic advice at the interface between IP, regulatory and commercial law. With a science degree and first-hand experience of the Life Sciences industry (including working in clinical trials before qualifying as a lawyer), Nicole is well placed to advise on issues relevant to the sector. Nicole is a member of CIPA’s life sciences committee.